Home > Oncology > ASCO 2022 > Gynaecological Cancers > Encouraging results of relacorilant in ovarian cancer

Encouraging results of relacorilant in ovarian cancer

Presented By
Prof. Nicoletta Colombo, University of Milan, Italy
ASCO 2022
The glucocorticoid receptor modulator relacorilant added to nab-paclitaxel demonstrated an overall survival (OS) benefit over nab-paclitaxel alone in patients with platinum-resistant/refractory ovarian cancer. These results provide evidence that cortisol modulation is a promising novel modality in oncology. A phase 2 study randomised 178 patients with recurrent platinum-resistant ovarian cancer to intermittent relacorilant plus nab-paclitaxel, continuous relacorilant plus nab-paclitaxel, or nab-paclitaxel alone. The primary analysis showed a significantly improved median progression-free survival (PFS) for patients in the intermittent arm compared with the nab-paclitaxel alone arm (5.55 vs 3.76 months; HR 0.66; log-rank P=0.038). Prof. Nicoletta Colombo (University of Milan, Italy) presented the final results of the study, including mature OS results [1]. The updated PFS rates were similar with those of the primary analysis, with a median ...

Please login to read the full text of the article.

If you have no account yet, please register now.

Posted on